Item 2.02 Results of Operations and Financial Condition.
On May 5, 2021, Horizon Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2021. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 29, 2021, Barry Moze, our Executive Vice President, Chief Administrative Officer, informed us that he will be retiring in January 2022. Mr. Moze’s current responsibilities will be assumed by existing executive officers. In connection with his retirement, and in exchange for a release of claims in favor of the Company, we agreed to provide benefits to Mr. Moze consisting of (i) 18 months continuation of health benefits, (ii) continued eligibility for his annual 2021 cash bonus based on performance against pre-established goals, (iii) an amendment to his existing stock options to extend the exercise period through the term of the options and (iv) continued vesting of his restricted stock units and performance stock units (contingent upon meeting the pre-established performance metrics).
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
